Grifols (GIFLF) Raw Materials (2010 - 2025)
Grifols' (GIFLF) quarterly Raw Materials came in at $1.1 billion in Q4 2025, up 6.71% on a YoY basis from $1.0 billion in Q4 2024, and up 6.71% quarter-over-quarter from $1.0 billion in Q4 2024.
Analysis
Grifols (GIFLF) Raw Materials (2010 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Raw Materials for 12 consecutive years, with $1.1 billion the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Raw Materials rose 6.71% year-over-year to $1.1 billion; the trailing twelve-month figure through Dec 2025 stood at $1.1 billion (up 6.71% YoY), and the FY2025 full-year result was $1.1 billion, up 3.57% from the prior year.
- Raw Materials advanced to $1.1 billion in Q4 2025 per GIFLF's latest filing, from $1.0 billion in the prior quarter.
- Across five years, Raw Materials topped out at $1.2 billion in Q4 2023 and bottomed at $751.7 million in Q4 2021.
- Historically, Raw Materials has averaged $1.0 billion across 5 years, with a median of $1.1 billion in 2022.
- The sharpest annual moves came in 2022 and 2024: Raw Materials jumped 44.53% in 2022, then fell 13.12% in 2024.
- Over 5 years, Raw Materials stood at $751.7 million in 2021, then soared by 44.53% to $1.1 billion in 2022, then grew by 8.18% to $1.2 billion in 2023, then slipped by 13.12% to $1.0 billion in 2024, then climbed by 6.71% to $1.1 billion in 2025.
- According to Business Quant data, Raw Materials over the past three periods registered $1.1 billion, $1.0 billion, and $1.2 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 1.09 Bn |
| Dec 31, 2024 | 1.02 Bn |
| Dec 31, 2023 | 1.18 Bn |
| Dec 31, 2022 | 1.09 Bn |
| Dec 31, 2021 | 751.66 Mn |
| Dec 31, 2020 | 709.88 Mn |
| Dec 31, 2019 | 847.97 Mn |
| Dec 31, 2018 | 738.94 Mn |
| Dec 31, 2017 | 534.99 Mn |
| Dec 31, 2016 | 457.08 Mn |
| Sep 30, 2011 | 42.44 Mn |
| Sep 30, 2010 | 17.69 Mn |